Tempus was founded in 2015 by Groupon co-founder Eric Lefkofsky. The company has not officially endorsed a plan to participate in an IPO.
Tempus provides genomic testing and data analysis with a focus on providing physicians a robust analytics tool that allows them to provide personalized cancer care for patients, though the company has indicated the scope may expand to include other conditions such as diabetes. The company has raised $620 million in Venture Capital funding from investors including Franklin Templeton, T. Rowe Price, Baillie Gifford, New Enterprise Associates, Revolution Group, Lightbank, and Revolution. Per company press releases, Tempus last raised $100 million in March 2020 at a post-money valuation of $5 billion.